Blueprint Medicines price target raised to $99 from $90 at Oppenheimer

Oppenheimer raised the firm’s price target on Blueprint Medicines to $99 from $90 and keeps an Outperform rating on the shares after Blueprint reported Q4 results that included a “nice beat” on Ayvakit sales. Arguably more important was bullish 2024 guidance that was well above the firm’s estimate and in line with consensus, added the analyst. While “not surprised to see the stock reacting positively today,” the firm adds “it probably would be up even more if not for some lingering concerns over script growth.”